Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542304 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Diuretics in Kidney Disease
A Phase 2 study, sponsored by Stanford University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT04542304: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT04542304 is a Phase 2 study that was terminated before completion, run by Stanford University. The registered enrollment target is 17 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04542304, a Phase 2 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will determine the efficacy of diuretics in patients with chronic kidney disease.
Primary Outcome
Average volume of urine produced in 24 hours.
Interventions
- DRUG Placebo
- DRUG Metolazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 2 |
Why NCT04542304 stopped before completion
NCT04542304 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04542304 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04542304 about?
NCT04542304 is a clinical study titled "Efficacy of Diuretics in Kidney Disease". This study will determine the efficacy of diuretics in patients with chronic kidney disease.
What is the current status of trial NCT04542304?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2021-03-01. Estimated completion is 2023-06-15.
What interventions are being tested in trial NCT04542304?
The interventions under investigation include: Placebo (DRUG), Metolazone (DRUG).
Who is sponsoring clinical trial NCT04542304?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04542304's enrollment target sits among peer trials
17 1903rd of 2000 higher than 93 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI